Immunosuppressants

Classification

Calcineurin inhibitors: cyclosporine, tacrolimus. mTOR inhibitors: sirolimus, everolimus. Antiproliferative: azathioprine, mycophenolate mofetil, methotrexate(low-dose, vs Cancer Chemo’s cytotoxic dose). Corticosteroids(full detail: Corticosteroids topic). Biologics: TNF-α inhibitors(infliximab, adalimumab, etanercept), IL-6 inhibitor(tocilizumab), anti-lymphocyte Ab(basiliximab, ATG).

T-Cell Activation Framework (organizing principle)

(1) TCR engagement → (2) calcineurin dephosphorylates NFAT → nuclear translocation → IL-2 transcription → (3) IL-2 autocrine binding own receptor → mTOR-mediated proliferation. Different drug classes block DIFFERENT numbered steps of SAME pathway.

Mechanism

Cyclosporine+tacrolimus: DIFFERENT immunophilin binding(cyclosporine=cyclophilin; tacrolimus=FKBP) but BOTH complexes inhibit SAME target: calcineurin → blocks NFAT dephosphorylation → blocks IL-2 transcription at SOURCE. Shared downstream target = why similar efficacy+core toxicity despite different starting chemistry. Shared NEPHROTOXICITY(dose-limiting — renal vasoconstriction+chronic interstitial fibrosis) — genuinely hard to distinguish from GRAFT REJECTION in kidney transplant(both = rising creatinine, needs biopsy). Tacrolimus MORE potent, largely displaced cyclosporine, but higher new-onset diabetes(direct β-cell toxicity) risk; cyclosporine = more gingival hyperplasia+hirsutism(shared feature with PHENYTOIN — different mechanism, same clinical sign).

Sirolimus/everolimus: bind SAME FKBP as tacrolimus, but complex inhibits mTOR not calcineurin → blocks IL-2 RECEPTOR signal transduction(step 3), DOWNSTREAM of calcineurin inhibitors(step 2) → blocks proliferation even WITH IL-2 present. → can COMBINE with calcineurin inhibitor for SYNERGY(sequential blockade, same logic as cotrimoxazole/sulfadiazine-pyrimethamine). NOT nephrotoxic(genuine advantage, no calcineurin renal vasoconstriction mechanism) → dose-sparing combination where nephrotoxicity is concern. Own toxicities: impaired wound healing(mTOR’s proliferation/repair role) + hyperlipidaemia.

Azathioprine: PRODRUG→6-MP(same active metabolite as Cancer Chemo topic) → further metabolized by TPMT. Reduced TPMT activity(genetic, actionable pharmacogenomic variant) → excess active thioguanine nucleotides → severe/fatal myelosuppression risk → TPMT testing before starting = standard practice, concrete pharmacogenomics example. Allopurinol interaction: inhibits xanthine oxidase(normally contributes to azathioprine/6-MP breakdown) → co-administration(genuinely arises, gout+transplant/autoimmune overlap) → ↑↑levels/myelosuppression risk → dose ↓65-75% if combo unavoidable — SEPARATE reason(from TPMT) for same amplified toxicity.

Mycophenolate mofetil: prodrug→mycophenolic acid → inhibits IMPDH(rate-limiting, DE NOVO purine synthesis). Lymphocytes MORE dependent on de novo pathway(vs other cells relying more on salvage pathway) → relative LYMPHOCYTE SELECTIVITY vs azathioprine’s broader effect → more favourable AE profile generally, but prominent GI SE(diarrhoea) specifically.

TNF-α inhibitors: neutralize TNF-α(central pro-inflammatory cytokine — RA, IBD, psoriasis) — DIFFERENT upstream cytokine-targeting mechanism vs T-cell-pathway drugs above. LATENT TB REACTIVATION = single most important risk(TNF-α required to maintain granuloma containing latent TB, neutralization → reactivation) → MANDATORY TB screening before starting — same screening logic as chronic corticosteroids, here MORE severely elevated risk.

Clinical Relevance

T-cell activation pathway framework makes calcineurin/mTOR inhibitors’ related-but-distinct mechanisms(same FKBP starting point for tacrolimus/sirolimus, different downstream target) coherent, not a list — directly explains WHY combine calcineurin inhibitor+mTOR inhibitor(sequential blockade, spares nephrotoxicity) in modern transplant protocols — SAME “why combine these two specific drugs” reasoning as antimicrobial/antitubercular pharmacology, applied to immunosuppression.

Classification

Calcineurin inhibitors: cyclosporine, tacrolimus
mTOR inhibitors: sirolimus (rapamycin), everolimus
Antiproliferative/antimetabolite agents: azathioprine, mycophenolate mofetil, methotrexate (already covered under Cancer Chemotherapy for its cytotoxic use, here at lower immunomodulatory doses)
Corticosteroids: already covered fully under Corticosteroids
Biologic agents: TNF-α inhibitors (infliximab, adalimumab, etanercept), IL-6 inhibitors (tocilizumab), anti-lymphocyte antibodies (basiliximab, antithymocyte globulin)

The T-Cell Activation Framework

Most immunosuppressants used in transplantation and autoimmune disease act at some point along the T-cell activation pathway, making this pathway the organizing framework for the topic: (1) antigen presentation and T-cell receptor engagement, (2) calcineurin-mediated dephosphorylation of NFAT (nuclear factor of activated T-cells), allowing NFAT to translocate to the nucleus and transcribe IL-2, (3) IL-2 binding its own receptor on the T-cell in an autocrine loop, driving mTOR-mediated cell cycle progression and clonal proliferation. Different drug classes intervene at different numbered steps of this same pathway.

Mechanism of Action

Cyclosporine and tacrolimus (calcineurin inhibitors): both bind an intracellular immunophilin protein first (cyclosporine binds cyclophilin, tacrolimus binds FKBP — different binding proteins, but both resulting drug-immunophilin complexes then inhibit the same target, calcineurin) — blocking calcineurin’s phosphatase activity prevents NFAT dephosphorylation/nuclear translocation, blocking IL-2 gene transcription at its source — this shared downstream target (despite different upstream binding proteins) is why cyclosporine and tacrolimus have broadly similar efficacy and similar core toxicity, worth understanding as two drugs converging on the identical final mechanism via different initial binding chemistry, rather than two unrelated mechanisms that happen to produce a similar clinical effect. Both share nephrotoxicity as their dose-limiting toxicity (direct renal vasoconstriction and, with chronic use, interstitial fibrosis — a genuine, ironic complication in transplant patients, since nephrotoxicity in a kidney transplant recipient specifically can be difficult to distinguish clinically from graft rejection, both presenting with rising creatinine, a specific, examined diagnostic challenge requiring biopsy to distinguish). Tacrolimus is generally more potent and has largely displaced cyclosporine in many transplant protocols, but carries a distinctly higher risk of new-onset diabetes after transplantation (direct pancreatic β-cell toxicity, a specific agent-to-agent distinction from cyclosporine) while cyclosporine carries a more prominent gingival hyperplasia and hirsutism profile (worth noting gingival hyperplasia as a shared feature with phenytoin under Antiepileptics — two mechanistically unrelated drugs producing the same distinctive clinical sign via different pathways).

Sirolimus/everolimus (mTOR inhibitors): also bind FKBP (the same immunophilin tacrolimus binds), but the resulting complex inhibits mTOR rather than calcineurin — blocking the IL-2 receptor signal transduction step (step 3 above) rather than IL-2 production itself (step 2), meaning sirolimus acts downstream of where calcineurin inhibitors act, blocking T-cell proliferation even in the presence of IL-2 rather than preventing IL-2 from being made in the first place — a genuinely distinct point of pathway interruption, which is why sirolimus can be combined with a calcineurin inhibitor for synergistic effect (blocking two sequential steps of the same pathway, the identical sequential-blockade synergy logic already seen with cotrimoxazole and sulfadiazine-pyrimethamine). Critically, sirolimus is not nephrotoxic (a genuinely distinguishing safety advantage over calcineurin inhibitors, since mTOR inhibition doesn’t share calcineurin’s renal vasoconstrictive mechanism), making it a specific alternative/dose-sparing combination partner in patients where calcineurin-inhibitor nephrotoxicity is a particular concern — but carries its own distinctive toxicities: impaired wound healing (mTOR’s role in normal cell proliferation/repair) and hyperlipidaemia.

Azathioprine: a prodrug, metabolized to 6-mercaptopurine (the same active metabolite already covered as a cytotoxic antimetabolite under Cancer Chemotherapy), which is further metabolized by thiopurine methyltransferase (TPMT) — patients with genetically reduced TPMT activity (a recognized, clinically actionable pharmacogenomic variation) accumulate excessive active thioguanine nucleotides and are at substantially increased risk of severe, potentially fatal myelosuppression at standard doses, the specific reason TPMT genotype/phenotype testing before starting azathioprine is increasingly standard practice — a genuinely concrete example of pharmacogenomics changing prescribing practice, not an abstract concept. Allopurinol interaction: allopurinol inhibits xanthine oxidase, an enzyme that normally contributes to azathioprine/6-MP breakdown — co-administration (a scenario that genuinely arises, since transplant/autoimmune patients may also have gout) substantially raises active drug levels and myelosuppression risk, requiring azathioprine dose reduction (typically by 65–75%) if the combination cannot be avoided — a specific, high-yield drug interaction distinct from the TPMT pharmacogenomic risk, worth keeping as two separate reasons the same toxicity (myelosuppression) can be amplified.

Mycophenolate mofetil: a prodrug, converted to mycophenolic acid, which inhibits inosine monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme in the de novo purine synthesis pathway — lymphocytes are relatively more dependent on de novo purine synthesis than most other cell types (which can rely more on the salvage pathway for purine supply), giving mycophenolate a degree of lymphocyte selectivity beyond the broader antiproliferative effect azathioprine has across more cell types generally — a specific, examined rationale for mycophenolate’s comparatively more favourable, more lymphocyte-selective adverse-effect profile relative to azathioprine’s broader marrow toxicity, though GI adverse effects (diarrhoea) are prominent with mycophenolate specifically.

Biologic agents (TNF-α inhibitors): neutralize TNF-α, a central pro-inflammatory cytokine in rheumatoid arthritis, inflammatory bowel disease, and psoriasis — a genuinely different, upstream-cytokine-targeting mechanism from the T-cell-pathway-targeted drugs above. Reactivation of latent tuberculosis is the single most important, specifically-examined risk of this class (TNF-α is required for maintaining the granuloma that contains latent TB infection, and its neutralization can allow reactivation) — mandatory TB screening before starting any TNF-α inhibitor is standard practice for exactly this mechanistic reason, the identical screening logic already noted for chronic corticosteroid therapy under Corticosteroids, here for a more specifically and severely elevated risk.

Clinical Relevance

The T-cell activation pathway framework is what makes calcineurin inhibitors’ and mTOR inhibitors’ genuinely distinct-but-related mechanisms (same immunophilin-binding starting point for tacrolimus/sirolimus, different downstream target) comprehensible as a coherent story rather than a list of unrelated facts, and it directly explains the specific rationale for combining a calcineurin inhibitor with an mTOR inhibitor (sequential pathway blockade, sparing nephrotoxicity) in modern transplant protocols — the same “why combine these two specific drugs” reasoning already established as a recurring theme across antimicrobial and antitubercular pharmacology, here applied to immunosuppression instead of infection.

T-cell activation pathway (TCR engagement → calcineurin/NFAT → IL-2 transcription → IL-2 receptor/mTOR → proliferation) with each drug class’s blocking point marked.
Cyclosporine/tacrolimus shared calcineurin target despite different immunophilin-binding starting points (cyclophilin vs FKBP).